that the results were excellent, with sensitivities approaching 97%, and reinforced the tremendous potential of this non-invasive technology
Bohemia, NY (PRWEB) June 2, 2008
Infrared Sciences Corp., the manufacturer of the Sentinel BreastScan breast cancer detection system, announced today it is exploring strategic alternatives, including a possible sale of the Company. Although an evaluation process is underway, including discussions with various interested parties, the Company has not set any time frame for conclusion of the process, and invites additional dialogue with all interested parties. Thomas DiCicco, ISC's President and CEO, said, "The Board and management are united in their efforts to diligently explore strategic alternatives and to maximize shareholder value. ISC has all the necessary ingredients that make an excellent healthcare investment opportunity including; tremendous market need, FDA clearance and CE Mark. The Sentinel BreastScan™ is currently generating revenue, it has completed clinical studies, has been presented at a major medical conference, and is pending publication in a peer review medical journal."
The Sentinel BreastScan, a non-invasive breast cancer detection system, has been undergoing clinical study for over 2 years at the Cornell Weill Medical College of Cornell University in New York City. The results of the study were approved and presented at the American Society of Breast Surgeons conference earlier this month, and are expected to be published in the American Journal of Surgery after the peer review process in the coming months. Thomas DiCicco commented that "that the results were excellent, with sensitivities approaching 97%, and reinforced the tremendous potential of this non-invasive technology". He added "that the Cornell study was the only recent study conducted in a prestigious academic institution of breast cancer detection utilizing state-of-the-art digital infrared imaging, and will be a major factor in the acceptance and expansion of the Sentinel BreastScan within main-stream medicine". The Sentinel BreastScan is unlike any other infrared system; being a fully automated dynamic test, employing artificial intelligence software, and a providing a fully interpreted real-time test report to the doctor. DiCicco added, "All women of any age stand to benefit from this technological leap forward, by providing their doctor with physiologic breast health data with a low cost, painless, non-invasive test; data that is not available from any other breast cancer test today."
About Infrared Sciences Corp.
Infrared Sciences Corp. is a New York-based technology company focused on the early detection of breast cancer. Its FDA-cleared and CE Mark approved, Sentinel BreastScan system has undergone more than 9 years of testing at several leading medical facilities, performing tests on over 20,000 patients. Installations of the Sentinel BreastScan system are progressing across the U.S and Europe, including on-going clinical studies at Cambridge University (UK) and the one recently concluded at Cornell.
Doctors interested in qualifying to receive a Sentinel BreastScan™ system, or Medical Product Distributors and Representatives interested in adding Sentinel BreastScan™ to their product lines, are invited to contact ISC. For more information contact Infrared Sciences Corporation, at 1650 Sycamore Ave. Suite 4, Bohemia, NY 11716. TEL: 631 240-9106, FAX: 631 750-3396, email@example.com, or visit http://www.infraredsciences.com.
# # #